Stock Ratings / Health Care / NUS / financials

ZSTK (31) ESYN (41) HLF (65) COSM (31) ⌘ Pro Terminal →

Nu Skin Enterprises Inc. (NUS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$4.69 -1.47% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.67

Nu Skin Enterprises Inc. (NUS) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $228.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.67 (-0.45%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 3.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+1.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NUS)Realized 20D OHLCV Swing Band: ±7.8%

Deterministic 5-Pillar Attribution (62/100 Composite)

🔍 WHY NUS SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (26% of score)

Altman Z-Score 3.54 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (26% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 43.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality6/20 pts (-14 pt drag)

Capital intensity & 4.4% operating margin leave 14 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$4.74+8.4% Next Q

Q2 (-2Q)

Grade B-$5.14-6.8% Next Q

Q3 (-1Q)

Grade C+$4.79-2.1% Next Q

Current

Grade C$4.69+0.7% Hist 90D α

Trajectory: B (70) → C (62)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NUS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, NUS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 66.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.77) or 200D SMA ($6.39) invalidates the momentum regime and cuts Target Base ($4.77) toward Bear Floor ($3.72).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NUS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NUS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 62%NO 38%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NUS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$46.0M (3.1% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.97B

FY24

Rev $1.73B

FY25

Rev $1.49B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.49B	69.4%	4.4%	$160.2M	$46.0M	6.7%
FY 2024	$1.73B	68.2%	-8.8%	-$146.6M	$70.2M	-14.5%
FY 2023	$1.97B	69.4%	2.5%	$8.6M	$118.6M	6.7%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NUS)

✓Walkthrough of NUS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.75%🛡️ HOLDING TREND SUPPORT

2026-10-30O $4.71H $4.80L $4.63C $4.69VOL 351.5K

RES: $5.36SUP: $4.43SMA50: $4.77SMA200: $6.39

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NUS Butterfly Map → + Track NUS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -14.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NUS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NUS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NUS)

Health Care Rank #172 of 1016 ⚔️ ZSTK vs NUS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NUS vs. ZSTK, ESYN, HLF, COSM)

Industry: Other Pharmaceuticals (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nu Skin Enterprises Inc. (NUS) ranks #172 by composite RQD confidence (62/100, grade C) and #559 by equity capitalization ($228.3M). Within this direct 5-issuer industry benchmark cohort, HLF leads on earnings valuation at 5.9x trailing P/E, while HLF leads on capital efficiency and profitability with 34.4% ROIC and 77.9% gross margin. HLF currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with NUS at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NUS ACTIVE Nu Skin Enterprises Inc.	C	62/100	—	69.4%	6.7%	-1.47%	$228.3M	Benchmark Subject
ZSTK ZeroStack Corp.	E	31/100	—	4.6%	-35.0%	-0.34%	$63.9M	/zstk-vs-nus →
ESYN EnerSyn Global Inc.	D-	41/100	—	53.0%	-35.0%	+3.10%	$54.4M	/esyn-vs-nus →
HLF Herbalife Ltd.	C	65/100	5.9x	77.9%	34.4%	-3.36%	$1.36B	/hlf-vs-nus →
COSM Cosmos Health Inc.	E	31/100	—	12.1%	-35.0%	+11.45%	$27.9M	/cosm-vs-nus →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001021561

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nu Skin Enterprises Inc. (NUS) reported GAAP revenue of $1.49B (-14.3% vs. FY2024 revenue of $1.73B , and -24.6% cumulative change since FY2023) , GAAP net income of $160.2M, operating cash flow of $80.3M, and free cash flow of $46.0M (-34.4% YoY). On the balance sheet, NUS closed FY2025 with $1.41B in total assets against $204.2M in total debt (Altman Z-Score: 3.54, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.49B	$160.2M	$80.3M	$46.0M	$1.41B	$204.2M
FY2024 (FY)	2024-12-31	$1.73B	-$146.6M	$111.7M	$70.2M	$1.47B	$363.6M
FY2023 (FY)	2023-12-31	$1.97B	$8.6M	$118.6M	$118.6M	—	—

3. NUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nu Skin Enterprises Inc. (NYSE: NUS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $4.69 (-1.47% 1D, market cap $228.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, NUS ranks #172 in composite RQD confidence.

How does NUS compare to ZSTK and ESYN in the Health Care sector?

Within the Health Care sector (Other Pharmaceuticals), NUS carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of 69.4%, and ROIC of 6.7%. By comparison, ZSTK (ZeroStack Corp.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $63.9M) and ESYN (EnerSyn Global Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $54.4M). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while HLF leads on capital efficiency (34.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NUS?

Per NUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001021561), Nu Skin Enterprises Inc. generated $1.49B in revenue (-14.3% YoY), $160.2M in net income, and $46.0M in free cash flow against $1.41B in total assets and $204.2M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NUS trading relative to its 50-day, 200-day, and 52-week technical levels?

NUS last traded at $4.69 (-1.47% on volume of 253,047 shares), positioning the stock -1.68% below its 50-day simple moving average ($4.77) and -26.60% below its 200-day simple moving average ($6.39). Across its 52-week range of $4.45 to $11.67, NUS sits at the 3.3% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±7.8% ($4.32 to $5.06).